2022
Leading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020
Faust JS, Chen AJ, Tiako M, Du C, Li SX, Krumholz HM, Barnett ML. Leading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020. JAMA Internal Medicine 2022, 182: 87-90. PMID: 34807250, PMCID: PMC8609460, DOI: 10.1001/jamainternmed.2021.6734.Peer-Reviewed Original Research
2002
Evaluation of a consumer-oriented internet health care report card. The risk of quality ratings based on mortality data
Krumholz H, Rathore S, Chen J, Wang Y, Radford M. Evaluation of a consumer-oriented internet health care report card. The risk of quality ratings based on mortality data. ACC Current Journal Review 2002, 11: 18. DOI: 10.1016/s1062-1458(02)00689-x.Peer-Reviewed Original Research
1995
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
Kalish S, Gurwitz J, Krumholz H, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Journal Of General Internal Medicine 1995, 10: 321-330. PMID: 7562123, DOI: 10.1007/bf02599951.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTissue plasminogen activatorAcute myocardial infarctionAdditional quality-adjusted life yearMyocardial infarctionGUSTO trialThrombolytic therapyOne-year mortality dataOccluded Coronary Arteries (GUSTO-I) trialMortality dataPlasminogen activatorLong-term medical costsCoronary Arteries trialOne-year mortalityUse of streptokinaseInferior wall infarctionCost-effective therapyCost-effectiveness modelDecision analysis modelSurvival benefitSymptom onsetClinical outcomesRelative survival advantageThrombolytic agentsSurvival advantage